Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Chelator Therapy for Slowing Renal Function Progression in Patients With Type 2 Diabetic Nephropathy Combined With Lead Burden
NCT07706946Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Jan 2029
01
Overview
Open-label, single-arm trial of edetate calcium disodium in diabetic glomerulosclerosis, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change in estimated glomerular filtration rate at 12 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
edetate calcium disodium
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on NCT07706946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706946.